Table 3.
The classification of CA-AKI patients by RIFLE criteria from baseline to hospital discharge day in CA-AKI patients
| CA-AKI (N = 52) | Baseline | Contrast use within 72 h | ICU Discharge | Hospital discharge |
|---|---|---|---|---|
| Risk | 11(21%) | 16(31%) | 6(12%) | 11(21%) |
| Injury | 4(7%) | 16(31%) | 10(19%) | 9(17%) |
| Failure | 14(27%) | 16(38%) | 23(44%) | 20(39%) |
| Loss | 3(6%) | |||
| ESKD | ||||
| Recovery | 13(25%) | 9(17%) |
Data are presented as N (%).
CA-AKI occurred in 52 patients. 30 patients had acute kidney injury before contrast administration already, by RIFLE criteria. Thus, there were new developed 22 CA-AKI patients within 72 hours after contrast use. Baseline means immediately prior to contrast administration.
ICU discharge: average 6.5 days after contrast use.
Hospital discharge: average 29 days after contrast use.
RIFLE classification.
Risk SCr × 1.5, < 0.5 ml/kg/h × 6 h.
Injury SCr × 2, < 0.5 ml/kg/h × 12 h.
Failure SCr × 3, or SCr ≥ 4 mg/dl with an acute rise > 0.5 mg/dl,< 0.3 ml/kg/h × 24 h or anuria × 12 h.
Loss persistent acute renal failure = complete loss of kidney function > 4 weeks.
ESKD End-stage kidney disease > 3 months.
CA-AKI contrast-associated acute kidney injury, ICU intensive care unit, RIFLE Risk, Injury, Failure, Loss, and End-stage Kidney, SCr serum creatinine, ESKD end stage kidney disease.